Adrian Zumsteg - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Adrian Zumsteg

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Diabetologia|December 24, 2015

Hyperglycaemia attenuates in vivo reprogramming of pancreatic exocrine cells to beta cells in miceClaudia Cavelti-Weder, Weida Li, Adrian Zumsteg, et al.

The Journal of Experimental Medicine|April 27, 2005

Identification of proteoglycans as the APRIL-specific binding partnersKarine Ingold, Adrian Zumsteg, Aubry Tardivel, et al.

Leukemia|September 13, 2018

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemiaKristina Klupsch, Vanessa Baeriswyl, Roland Scholz, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Diabetologia|December 24, 2015

Hyperglycaemia attenuates in vivo reprogramming of pancreatic exocrine cells to beta cells in miceClaudia Cavelti-Weder, Weida Li, Adrian Zumsteg, et al.

The Journal of Experimental Medicine|April 27, 2005

Identification of proteoglycans as the APRIL-specific binding partnersKarine Ingold, Adrian Zumsteg, Aubry Tardivel, et al.

Leukemia|September 13, 2018

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemiaKristina Klupsch, Vanessa Baeriswyl, Roland Scholz, et al.

Pageof 2